Le Lézard
Classified in: Health, Business
Subjects: PER, VEN

410 Medical Secures $8 Million in Series A Financing, Expands Board of Directors

DURHAM, N.C., Oct. 22, 2019 /PRNewswire/ -- 410 Medical, Inc., a medical device company developing innovative technologies for critical care, announced today it has closed on a Series A financing of $8 million led by Hatteras Venture Partners, with participation from OSF Healthcare and existing investors including Sovereign's Capital. 410's lead product, LifeFlow®, is designed to enable clinicians to more effectively and efficiently deliver fluids to critically ill patients.  

410 Medical, Inc., a medical device company focused on developing innovative technologies for the resuscitation of critically ill patients. (PRNewsfoto/410 Medical, Inc.)

"LifeFlow has been designed to deliver fluids up to 10 times faster than traditional methods, which can be particularly impactful for patients suffering from sepsis, shock and trauma, who are at higher risk of organ failure and death," said Kyle Chenet, Chief Executive Officer at 410 Medical. "This new funding will be instrumental in expanding commercialization of LifeFlow in hospital and pre-hospital environments nationwide, ensuring that more patients receive time-sensitive fluid resuscitation."

Severe sepsis affects over 1 million adults and children each year in the US. It is the most frequent cause of death in hospitalized patients and the leading killer of children worldwide. Early, rapid delivery of fluid is a life-saving therapy, yet with existing methods providers often fail to achieve published fluid delivery guidelines.  Since FDA clearance in 2016, LifeFlow has seen increasing adoption at leading healthcare systems throughout the U.S., including Cincinnati Children's Hospital Medical Center, Children's Hospital Colorado, and WakeMed Health & Hospitals.

"We are thrilled to support the vision of 410 Medical's founders, to ensure LifeFlow can be in the hands of any clinician needing to provide rapid fluids for a critically ill patient," said Jeff Terrell, Partner at Hatteras. Mr. Terrell will be joining the 410 Medical Board of Directors along with Stan Lynall, Vice President of Venture Investments at OSF Ventures. OSF Ventures is the venture capital arm of OSF HealthCare, an Illinois-based health system with 124 locations and 13 hospitals.

About 410 Medical, Inc.
Founded in 2013, 410 Medical is a medical device company dedicated to developing innovative products that enable frontline medical providers to improve care for critically ill patients. 410 Medical's first product, LifeFlow, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening illnesses such as sepsis and shock. LifeFlow was cleared by the FDA for human use in 2016. For more information, visit www.410medical.com.

About Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm based in Durham, N.C., with a focus on seed and early stage opportunities across the health care continuum from transformative therapies to disruptive technologies. The firm has six funds and over $550 million in capital commitments under management. Hatteras is led by a seasoned team of entrepreneurs and operators and has a long and successful track record of seed and early stage investing and company formation. To learn more about Hatteras Venture Partners, please visit www.hatterasvp.com.

About OSF Ventures
OSF Ventures specializes in venture optimization, partnering financially and operationally in companies that improve patient outcomes and reduce costs to health care systems. OSF Ventures is a division of OSF HealthCare. More at www.osfventures.org.

SOURCE 410 Medical, Inc.

These press releases may also interest you

at 10:50
AstraZeneca today announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that FARXIGA (dapagliflozin) reduced the risk of the primary composite outcome of worsening heart failure (HF), defined as...

at 10:50
A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that Jardiance® (empagliflozin) was associated with a decreased risk of hospitalization for heart...

at 10:45
Mezzion Pharma Co. Ltd. (140410: KOSDAQ) today announces the presentation of data from its pivotal clinical trial for its new orphan drug for the treatment of adolescents with single ventricle heart disease. Dr. David...

at 10:45
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1   Entresto, compared to valsartan, demonstrated reduced risk in total heart failure hospitalizations and...

at 08:00
The College of Health Care Professions (CHCP), the largest allied health training institution in Texas, today announced that its Houston campuses and offices were honored as a 2019 Top Workplace by the Houston Chronicle. The award, which recognizes...

16 nov 2019
Footit Medical Supply, a durable medical equipment, mobility, & CPAP provider, announced the promotion of Natalia Sinigur as Vice President of its organization moving forward. Also, Sinigur has exercised her stock option rights and currently owns 35%...

News published on 22 october 2019 at 08:15 and distributed by: